Latest News

Linda Chan, MSN, RN, ONC, CMSRN, EBP-C, emphasized that patients should check with providers regarding the removal of larger heparin lines for flushes.

The incidence rate of occlusions per 1000 central line days was 10.68 in the pre-EBP change cohort and 21.00 in the post-EBP change cohort.

Hua-Jay Cherng, MD, explored how ctDNA and MRD are shifting from theoretical markers to actionable clinical tools in DLBCL.

Hua-Jay Cherng, MD, described the “threefold” benefits of taking part in training programs among junior investigators in lymphoma.

Experts discuss how checkpoint inhibitors, cystectomy, and other treatment modalities fit into the current landscape for non–muscle-invasive bladder cancer.

Phase 1/2 findings from the BGB-11417-201 trial support the FDA approval of sonrotoclax in relapsed/refractory mantle cell lymphoma.

CAR T-cell therapies and bispecific antibodies are still in their infancy, according to Barry Paul, MD.

Investigators are currently evaluating emiltatug ledadotin among patients with different solid tumors in a phase 1 trial.

The 36-month DOR rate was 64.5% among patients who achieved a 3-month CR with mitomycin for low-grade intermediate-risk non-muscle invasive bladder cancer.

According to Timothy A. Yap, MBBS, PhD, FRCP, there is an unmet need in oncology for treating patients with CCNE1, FBXW7, and PPP2R1A genomic alterations.

Muhammad Umair Mushtaq, MD, explains how TIL therapy offers a 30% response rate for patients with metastatic melanoma in whom prior treatments have failed.

Zoldonrasib has elicited good responses and progression-free survival in an area with a large unmet need, said Jonathan Wesley Riess, MD, MS.

The safety profile of zoldonrasib appeared to be “superb” among patients with NSCLC harboring KRAS G12D mutations, said Jonathan Wesley Riess, MD, MS.

Timothy A. Yap, MBBS, PhD, FRCP, presented data from the MYTHIC trial, demonstrating a 60% ORR at the RP2D in patients with CCNE1-amplified PROC.

Steven M. Horwitz, MD, discussed the PRIMO dosing strategy to manage adverse effects in lymphoma.

Muhammad Umair Mushtaq, MD, discussed the evolution of TIL therapy in melanoma, focusing on first-line treatment potential and immune fitness.

Grade 3 or higher TRAEs occurred in 14% of patients treated with NDI-101150, including 1 incidence of grade 4 aplastic anemia across all comers in the study.

The FDA has granted RMAT designation to RZ-001, a first-in-class RNA trans-splicing ribozyme gene therapy, for the management of hepatocellular carcinoma.

Experts highlight advances in cellular therapies that were discussed at the 2026 National ICE-T Conference in Charlotte, North Carolina.

Jennifer Effie Amengual, MD, detailed a clinical trial evaluating the dual epigenetic combination of tazemetostat and belinostat for the treatment of T-cell lymphomas.